Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID	DTD0019 Transporter Info
Gene Name	SLC10A1
Transporter Name	Sodium/taurocholate cotransporting polypeptide
Gene ID	6554
UniProt ID	Q14973

Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)
Chemical Compound
DT Modulation1	Cyclosporine affects the expression of SLC10A1 mRNA			[56]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Cyclosporine inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Cyclosporine inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Cyclosporine inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Cyclosporine results in decreased activity of SLC10A1 protein			[57]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Cyclosporine results in decreased activity of SLC10A1 protein which affects the abundance of Cholic Acids			[57]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Cyclosporine results in decreased expression of SLC10A1 mRNA			[15]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Bosentan results in decreased expression of SLC10A1 mRNA			[21]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Furosemide results in decreased activity of SLC10A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	SLC10A1 protein results in increased uptake of Cholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Cholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Phenobarbital results in increased expression of SLC10A1 protein			[69]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Cocaine results in increased expression of SLC10A1 mRNA			[11]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol results in increased expression of SLC10A1			[60]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Troglitazone inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Troglitazone inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Troglitazone inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Tolvaptan metabolite results in decreased activity of SLC10A1 protein			[19]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Valproic Acid results in decreased activity of SLC10A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Dexamethasone results in increased expression of SLC10A1 mRNA			[59]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Ritonavir results in decreased expression of SLC10A1			[71]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Irbesartan inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Irbesartan inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Irbesartan inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Benzo(a)pyrene results in increased expression of SLC10A1 mRNA			[50]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	TAK-875 inhibits the reaction SLC10A1 protein results in increased transport of Bile Acids and Salts			[74]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	TAK-875 results in decreased activity of SLC10A1 protein			[74]
Regulation Mechanism				Transcription Factor Info
4-cresol sulfate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-cresol sulfate inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[44]
Regulation Mechanism				Transcription Factor Info
Acetamides	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acetamides analog inhibits the reaction SLC10A1 protein results in increased transport of Taurocholic Acid			[45]
Regulation Mechanism				Transcription Factor Info
afimoxifene	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	afimoxifene results in decreased expression of SLC10A1 mRNA			[24]
Regulation Mechanism				Transcription Factor Info
Albuterol	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Albuterol results in increased expression of SLC10A1 mRNA			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Albuterol results in increased expression of SLC10A1 protein			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Carvedilol co-treated with Albuterol results in decreased expression of SLC10A1 protein			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Carvedilol inhibits the reaction Albuterol results in increased expression of SLC10A1 mRNA			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Carvedilol inhibits the reaction Albuterol results in increased expression of SLC10A1 protein			[47]
Regulation Mechanism				Transcription Factor Info
Amoxicillin-Potassium Clavulanate Combination	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC10A1 mRNA			[40]
Regulation Mechanism				Transcription Factor Info
aristolochic acid I	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	aristolochic acid I results in increased expression of SLC10A1 mRNA			[48]
Regulation Mechanism				Transcription Factor Info
Asbestos, Serpentine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Asbestos, Serpentine results in increased expression of SLC10A1 mRNA			[49]
Regulation Mechanism				Transcription Factor Info
Atazanavir Sulfate	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Atazanavir Sulfate results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
baohuoside I	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	baohuoside I results in increased expression of SLC10A1 protein			[41]
Regulation Mechanism				Transcription Factor Info
beta-Naphthoflavone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	beta-Naphthoflavone results in decreased expression of SLC10A1 mRNA			[32]
Regulation Mechanism				Transcription Factor Info
betulin	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	betulin affects the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	betulin inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
Betulinic Acid	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Betulinic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Betulinic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Betulinic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
bisphenol A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol A inhibits the reaction Sodium co-treated with SLC10A1 protein results in increased uptake of Taurocholic Acid			[36]
Regulation Mechanism				Transcription Factor Info
bisphenol F	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol F inhibits the reaction Sodium co-treated with SLC10A1 protein results in increased uptake of Taurocholic Acid			[36]
Regulation Mechanism				Transcription Factor Info
Carvedilol	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Carvedilol co-treated with Albuterol results in decreased expression of SLC10A1 protein			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Carvedilol inhibits the reaction Albuterol results in increased expression of SLC10A1 mRNA			[47]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Carvedilol inhibits the reaction Albuterol results in increased expression of SLC10A1 protein			[47]
Regulation Mechanism				Transcription Factor Info
CGP 52608	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	CGP 52608 promotes the reaction RORA protein binds to SLC10A1 gene			[52]
Regulation Mechanism				Transcription Factor Info
Chenodeoxycholic Acid	12 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Chenodeoxycholic Acid results in decreased expression of SLC10A1 mRNA			[53]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	SLC10A1 protein results in increased uptake of Chenodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation12	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Chenodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
chlortoluron	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	chlortoluron results in decreased expression of SLC10A1 mRNA			[54]
Regulation Mechanism				Transcription Factor Info
cholylsarcosine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC10A1 protein results in increased uptake of cholylsarcosine			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of cholylsarcosine			[51]
Regulation Mechanism				Transcription Factor Info
Clavulanic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Clavulanic Acid results in decreased expression of SLC10A1 mRNA			[40]
Regulation Mechanism				Transcription Factor Info
Clopidogrel	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Clopidogrel results in decreased activity of SLC10A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
Crack Cocaine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Crack Cocaine results in decreased expression of SLC10A1 mRNA			[11]
Regulation Mechanism				Transcription Factor Info
daidzein	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	daidzein metabolite inhibits the reaction SLC10A1 protein results in increased transport of estrone sulfate			[58]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	daidzein metabolite promotes the reaction SLC10A1 protein results in increased transport of estrone sulfate			[58]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	estrone sulfate inhibits the reaction SLC10A1 protein results in increased transport of daidzein metabolite			[58]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	SLC10A1 protein results in increased transport of daidzein metabolite			[58]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Taurocholic Acid inhibits the reaction SLC10A1 protein results in increased transport of daidzein metabolite			[58]
Regulation Mechanism				Transcription Factor Info
Dehydroepiandrosterone Sulfate	12 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Betulinic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Cyclosporine inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Dehydroepiandrosterone Sulfate inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Dehydroepiandrosterone Sulfate inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Dehydroepiandrosterone Sulfate inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Erythrosine inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Irbesartan inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	Sulfobromophthalein inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	Taurolithocholic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation12	Troglitazone inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
Deoxycholic Acid	11 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	SLC10A1 protein results in increased uptake of Deoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Deoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
Diclofenac	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Diclofenac results in decreased activity of SLC10A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
Erythrosine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Erythrosine inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Erythrosine inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Erythrosine inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
estrone sulfate	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	daidzein metabolite inhibits the reaction SLC10A1 protein results in increased transport of estrone sulfate			[58]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	daidzein metabolite promotes the reaction SLC10A1 protein results in increased transport of estrone sulfate			[58]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	estrone sulfate inhibits the reaction SLC10A1 protein results in increased transport of daidzein metabolite			[58]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	SLC10A1 protein results in increased uptake of estrone sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of estrone sulfate			[51]
Regulation Mechanism				Transcription Factor Info
Ethambutol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol results in increased expression of SLC10A1			[60]
Regulation Mechanism				Transcription Factor Info
Ezetimibe	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ezetimibe inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
Fluorescein-5-isothiocyanate	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC10A1 protein results in increased uptake of Fluorescein-5-isothiocyanate			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Taurocholic Acid promotes the reaction SLC10A1 protein results in increased uptake of Fluorescein-5-isothiocyanate			[61]
Regulation Mechanism				Transcription Factor Info
Fusidic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fusidic Acid inhibits the reaction SLC10A1 protein results in increased transport of Taurocholic Acid			[62]
Regulation Mechanism				Transcription Factor Info
Glycochenodeoxycholic Acid	11 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	SLC10A1 protein results in increased uptake of Glycochenodeoxycholic Acid			[63]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Glycochenodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
Glycocholic Acid	11 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	SLC10A1 protein results in increased uptake of Glycocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Glycocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
Glycodeoxycholic Acid	10 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Glycodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
glycoursodeoxycholic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of glycoursodeoxycholic acid			[51]
Regulation Mechanism				Transcription Factor Info
heliotrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	heliotrine results in decreased expression of SLC10A1 mRNA			[35]
Regulation Mechanism				Transcription Factor Info
Hexachlorocyclohexane	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Hexachlorocyclohexane results in decreased expression of SLC10A1 mRNA			[16]
Regulation Mechanism				Transcription Factor Info
hippuric acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	hippuric acid results in increased expression of SLC10A1 mRNA			[44]
Regulation Mechanism				Transcription Factor Info
Indican	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Indican results in decreased expression of SLC10A1 mRNA			[44]
Regulation Mechanism				Transcription Factor Info
Indocyanine Green	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Nifedipine promotes the reaction SLC10A1 protein results in increased uptake of Indocyanine Green			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC10A1 protein results in increased uptake of Indocyanine Green			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Taurocholic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Indocyanine Green			[61]
Regulation Mechanism				Transcription Factor Info
indoleacetic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	indoleacetic acid results in increased expression of SLC10A1 mRNA			[44]
Regulation Mechanism				Transcription Factor Info
Isoniazid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol results in increased expression of SLC10A1			[60]
Regulation Mechanism				Transcription Factor Info
Levofloxacin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Levofloxacin results in decreased activity of SLC10A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
Losartan	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Losartan inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Losartan inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
lupenone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	lupenone affects the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	lupenone inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
macitentan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	macitentan results in decreased expression of SLC10A1 mRNA			[21]
Regulation Mechanism				Transcription Factor Info
methyleugenol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	methyleugenol results in decreased expression of SLC10A1 mRNA			[38]
Regulation Mechanism				Transcription Factor Info
NCS 382	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	NCS 382 results in increased expression of SLC10A1 mRNA			[64]
Regulation Mechanism				Transcription Factor Info
nefazodone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	nefazodone results in decreased expression of SLC10A1 mRNA			[25]
Regulation Mechanism				Transcription Factor Info
Nifedipine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Nifedipine promotes the reaction SLC10A1 protein results in increased uptake of Indocyanine Green			[61]
Regulation Mechanism				Transcription Factor Info
obeticholic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	obeticholic acid results in decreased expression of SLC10A1 mRNA			[12]
Regulation Mechanism				Transcription Factor Info
Okadaic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Okadaic Acid results in decreased expression of SLC10A1 mRNA			[65]
Regulation Mechanism				Transcription Factor Info
oltipraz	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	oltipraz results in decreased expression of SLC10A1 mRNA			[10]
Regulation Mechanism				Transcription Factor Info
o,p'-DDT	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	o,p'-DDT results in decreased expression of SLC10A1 mRNA			[16]
Regulation Mechanism				Transcription Factor Info
perfluorobutanesulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC10A1 protein results in increased transport of perfluorobutanesulfonic acid			[66]
Regulation Mechanism				Transcription Factor Info
perfluorodecanesulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluorodecanesulfonic acid results in increased expression of SLC10A1 mRNA			[39]
Regulation Mechanism				Transcription Factor Info
perfluorohexanesulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC10A1 protein results in increased transport of perfluorohexanesulfonic acid			[66]
Regulation Mechanism				Transcription Factor Info
perfluorooctane sulfonic acid	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluorooctane sulfonic acid affects the expression of SLC10A1 mRNA			[68]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	perfluorooctane sulfonic acid results in increased expression of SLC10A1 mRNA			[39]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC10A1 protein results in increased transport of perfluorooctane sulfonic acid			[66]
Regulation Mechanism				Transcription Factor Info
perfluorooctanoic acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluorooctanoic acid affects the expression of SLC10A1 mRNA			[68]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	perfluorooctanoic acid results in increased expression of SLC10A1 mRNA			[39]
Regulation Mechanism				Transcription Factor Info
Pioglitazone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pioglitazone results in decreased activity of SLC10A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
pregnenolone sulfate	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC10A1 protein results in increased uptake of pregnenolone sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of pregnenolone sulfate			[51]
Regulation Mechanism				Transcription Factor Info
Primidone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Primidone results in decreased activity of SLC10A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
propiconazole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	propiconazole results in decreased expression of SLC10A1 mRNA			[70]
Regulation Mechanism				Transcription Factor Info
Pyrazinamide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol results in increased expression of SLC10A1			[60]
Regulation Mechanism				Transcription Factor Info
Ro 41-5253	6 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ro 41-5253 inhibits the reaction RARA protein co-treated with RXRA protein results in increased expression of SLC10A1 mRNA			[17]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Ro 41-5253 inhibits the reaction RARB protein co-treated with RXRA protein results in increased expression of SLC10A1 mRNA			[17]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Ro 41-5253 inhibits the reaction RARG protein co-treated with RXRA protein results in increased expression of SLC10A1 mRNA			[17]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Ro 41-5253 results in decreased expression of SLC10A1 mRNA			[17]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Ro 41-5253 results in decreased expression of SLC10A1 protein			[17]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	SLC10A1 protein results in increased susceptibility to Ro 41-5253			[17]
Regulation Mechanism				Transcription Factor Info
Rosiglitazone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Rosiglitazone results in decreased activity of SLC10A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
senkirkine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	senkirkine results in decreased expression of SLC10A1 mRNA			[35]
Regulation Mechanism				Transcription Factor Info
Sodium	22 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol A inhibits the reaction Sodium co-treated with SLC10A1 protein results in increased uptake of Taurocholic Acid			[36]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	bisphenol F inhibits the reaction Sodium co-treated with SLC10A1 protein results in increased uptake of Taurocholic Acid			[36]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Sodium co-treated with SLC10A1 protein results in increased uptake of Taurocholic Acid			[36]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased import of Taurocholic Acid			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Chenodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Cholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of cholylsarcosine			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Deoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of estrone sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Glycochenodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation12	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Glycocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation13	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Glycodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation14	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of glycoursodeoxycholic acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation15	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of pregnenolone sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation16	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Taurochenodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation17	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation18	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Taurodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation19	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation20	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Ursodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation21	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of ursodoxicoltaurine			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation22	tetrabromobisphenol A inhibits the reaction Sodium co-treated with SLC10A1 protein results in increased uptake of Taurocholic Acid			[36]
Regulation Mechanism				Transcription Factor Info
sodium arsenite	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in decreased expression of SLC10A1 mRNA			[37]
Regulation Mechanism				Transcription Factor Info
Sulfobromophthalein	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sulfobromophthalein inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Sulfobromophthalein inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[73]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Sulfobromophthalein inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
sulfolithocholylglycine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC10A1 protein results in increased uptake of sulfolithocholylglycine			[63]
Regulation Mechanism				Transcription Factor Info
sulforaphane	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	sulforaphane results in decreased expression of SLC10A1 mRNA			[40]
Regulation Mechanism				Transcription Factor Info
Tartrazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
Taurochenodeoxycholic Acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC10A1 protein results in increased uptake of Taurochenodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Taurochenodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
Taurocholic Acid	36 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-cresol sulfate inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[44]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Acetamides analog inhibits the reaction SLC10A1 protein results in increased transport of Taurocholic Acid			[45]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Acetanilides analog promotes the reaction SLC10A1 protein results in increased transport of Taurocholic Acid			[45]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Anthraquinones analog inhibits the reaction SLC10A1 protein results in increased transport of Taurocholic Acid			[45]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Benzenesulfonates analog inhibits the reaction SLC10A1 protein results in increased transport of Taurocholic Acid			[45]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	betulin affects the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Betulinic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Bile Acids and Salts inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[75]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	bisphenol A inhibits the reaction Sodium co-treated with SLC10A1 protein results in increased uptake of Taurocholic Acid			[36]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	bisphenol F inhibits the reaction Sodium co-treated with SLC10A1 protein results in increased uptake of Taurocholic Acid			[36]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	Cyclosporine inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation12	Dehydroepiandrosterone Sulfate inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation13	Erythrosine inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation14	Ezetimibe inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation15	Fusidic Acid inhibits the reaction SLC10A1 protein results in increased transport of Taurocholic Acid			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation16	Irbesartan inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation17	Losartan inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation18	lupenone affects the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation19	Piperazines analog promotes the reaction SLC10A1 protein results in increased transport of Taurocholic Acid			[45]
Regulation Mechanism				Transcription Factor Info
DT Modulation20	SLC10A1 protein results in increased import of Taurocholic Acid			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation21	SLC10A1 protein results in increased transport of Taurocholic Acid			[45]
Regulation Mechanism				Transcription Factor Info
DT Modulation22	SLC10A1 protein results in increased uptake of Taurocholic Acid			[75]
Regulation Mechanism				Transcription Factor Info
DT Modulation23	Sodium co-treated with SLC10A1 protein results in increased uptake of Taurocholic Acid			[36]
Regulation Mechanism				Transcription Factor Info
DT Modulation24	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased import of Taurocholic Acid			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation25	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation26	Sulfobromophthalein inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[73]
Regulation Mechanism				Transcription Factor Info
DT Modulation27	Taurocholic Acid inhibits the reaction SLC10A1 protein results in increased transport of daidzein metabolite			[58]
Regulation Mechanism				Transcription Factor Info
DT Modulation28	Taurocholic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Indocyanine Green			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation29	Taurocholic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation30	Taurocholic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation31	Taurocholic Acid promotes the reaction SLC10A1 protein results in increased uptake of Fluorescein-5-isothiocyanate			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation32	Taurolithocholic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation33	tetrabromobisphenol A inhibits the reaction Sodium co-treated with SLC10A1 protein results in increased uptake of Taurocholic Acid			[36]
Regulation Mechanism				Transcription Factor Info
DT Modulation34	tetrahydrophthalamic acid analog inhibits the reaction SLC10A1 protein results in increased transport of Taurocholic Acid			[45]
Regulation Mechanism				Transcription Factor Info
DT Modulation35	Tobacco Smoke Pollution inhibits the reaction SLC10A1 protein results in increased import of Taurocholic Acid			[5]
Regulation Mechanism				Transcription Factor Info
DT Modulation36	Troglitazone inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
Taurodeoxycholic Acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC10A1 protein results in increased uptake of Taurodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Taurodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
Taurolithocholic Acid	16 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Betulinic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	betulin inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Cyclosporine inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Dehydroepiandrosterone Sulfate inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Erythrosine inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Irbesartan inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Losartan inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	lupenone inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	Sulfobromophthalein inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation12	Taurocholic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation13	Taurolithocholic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Dehydroepiandrosterone Sulfate			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation14	Taurolithocholic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Taurocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation15	Taurolithocholic Acid inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation16	Troglitazone inhibits the reaction SLC10A1 protein results in increased uptake of Taurolithocholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
tetrabromobisphenol A	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	tetrabromobisphenol A inhibits the reaction Sodium co-treated with SLC10A1 protein results in increased uptake of Taurocholic Acid			[36]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	tetrabromobisphenol A results in decreased activity of SLC10A1 protein			[36]
Regulation Mechanism				Transcription Factor Info
Tetrachlorodibenzodioxin	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tetrachlorodibenzodioxin affects the expression of SLC10A1 mRNA			[76]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Tetrachlorodibenzodioxin results in decreased expression of SLC10A1 mRNA			[10]
Regulation Mechanism				Transcription Factor Info
tetrahydrophthalamic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	tetrahydrophthalamic acid analog inhibits the reaction SLC10A1 protein results in increased transport of Taurocholic Acid			[45]
Regulation Mechanism				Transcription Factor Info
Theophylline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Theophylline results in decreased activity of SLC10A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
Thiram	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Thiram results in increased expression of SLC10A1 mRNA			[77]
Regulation Mechanism				Transcription Factor Info
Triclosan	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Triclosan results in decreased expression of SLC10A1 mRNA			[78]
Regulation Mechanism				Transcription Factor Info
Ursodeoxycholic Acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC10A1 protein results in increased uptake of Ursodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of Ursodeoxycholic Acid			[51]
Regulation Mechanism				Transcription Factor Info
ursodoxicoltaurine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC10A1 protein results in increased uptake of ursodoxicoltaurine			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Sodium deficiency inhibits the reaction SLC10A1 protein results in increased uptake of ursodoxicoltaurine			[51]
Regulation Mechanism				Transcription Factor Info
Valsartan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Valsartan results in decreased activity of SLC10A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
zafirlukast	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	zafirlukast results in decreased activity of SLC10A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
Nanoparticle
perfluoro-n-nonanoic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluoro-n-nonanoic acid results in decreased expression of SLC10A1 mRNA			[67]
Regulation Mechanism				Transcription Factor Info
Fungicide
tebuconazole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	tebuconazole results in decreased expression of SLC10A1 mRNA			[70]
Regulation Mechanism				Transcription Factor Info
Approved Drug
Cyclosporine	10 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cyclosporine inhibits the transportation of Rosuvastatin by SLC10A1 (IC50 = 0.37 microM)			[1]
Affected Drug/Substrate	Rosuvastatin	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-NTCP
DT Modulation2	Cyclosporine inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 1 microM)			[2]
Affected Drug/Substrate	Sodium taurocholate	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-NTCP
Bosentan	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bosentan inhibits the transportation of Sodium taurocholate by SLC10A1 (Ki = 18 microM)			[3]
Affected Drug/Substrate	Sodium taurocholate	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-NTCP
DT Modulation2	Bosentan inhibits the activity of SLC10A1			[3]
Gemfibrozil	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Gemfibrozil inhibits the transportation of Rosuvastatin by SLC10A1 (IC50 = 23 microM)			[1]
Affected Drug/Substrate	Rosuvastatin	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-NTCP
Chenodeoxycholic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chenodeoxycholic acid inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 3.6 microM)			[2]
Affected Drug/Substrate	Sodium taurocholate	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-NTCP
Furosemide	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Furosemide inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 15 microM)			[2]
Affected Drug/Substrate	Sodium taurocholate	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-NTCP
Ketoconazole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ketoconazole inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 264 microM)			[2]
Affected Drug/Substrate	Sodium taurocholate	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-NTCP
Propranolol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Propranolol inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 5.5 microM)			[2]
Affected Drug/Substrate	Sodium taurocholate	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-NTCP
Chlorpropamide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chlorpropamide inhibits the transportation of Sodium taurocholate by SLC10A1			[2]
Affected Drug/Substrate	Sodium taurocholate	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-NTCP
Progesterone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Progesterone inhibits the transportation of Sodium taurocholate by SLC10A1			[2]
Affected Drug/Substrate	Sodium taurocholate	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-NTCP
Caspofungin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Caspofungin inhibits the transportation of Sodium taurocholate by SLC10A1			[6]
Affected Drug/Substrate	Sodium taurocholate	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-NTCP
Everolimus	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Everolimus inhibits the uptake of taurocholate by SLC10A1			[7]
Affected Drug/Substrate	Taurocholate	Modulation Type	Inhibition
Cell System	Human hepatoma HuH-7 cells-NTCP1
Cholic Acid	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cholic Acid inhibits the expression of SLC10A1			[9]
Regulation Mechanism	via modulation of Bile acid receptor (NR1H4)			Transcription Factor Info
Cell System	C57/BL6 mice
Phenobarbital	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Phenobarbital inhibits the expression of SLC10A1			[10]
Regulation Mechanism	via modulation of Nuclear receptor subfamily 1 group I member 3 (NR1I3)			Transcription Factor Info
Cell System	Human primary human hepatocytes
Cocaine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cocaine inhibits the expression of SLC10A1			[11]
Obeticholic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Obeticholic acid inhibits the expression of SLC10A1			[12]
Carmustine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Carmustine increases the expression of SLC10A1			[13]
Rifampin	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Rifampin inhibits the expression of SLC10A1			[10]
Carbamazepine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Carbamazepine increases the expression of SLC10A1			[14]
Estradiol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Estradiol inhibits the expression of SLC10A1			[15]
Lindane	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Lindane inhibits the expression of SLC10A1			[16]
Tretinoin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tretinoin inhibits the expression of SLC10A1			[17]
Fenofibrate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fenofibrate inhibits the expression of SLC10A1			[18]
Troglitazone	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Troglitazone inhibits the expression of SLC10A1			[18]
Tolvaptan	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tolvaptan inhibits the activity of SLC10A1			[19]
Ethinyl Estradiol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ethinyl Estradiol inhibits the expression of SLC10A1			[20]
Macitentan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Macitentan inhibits the expression of SLC10A1			[21]
Acetaminophen	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acetaminophen inhibits the expression of SLC10A1			[22]
DT Modulation2	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLC10A1 mRNA			[46]
Regulation Mechanism				Transcription Factor Info
Valproic Acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Valproic Acid inhibits the expression of SLC10A1			[23]
Tamoxifen	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tamoxifen increases the expression of SLC10A1			[24]
Nefazodone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Nefazodone inhibits the expression of SLC10A1			[25]
Rifampicin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Rifampicin inhibits the activity of SLC10A1			[26]
Dexamethasone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dexamethasone induces the activity of SLC10A1			[27]
Ritonavir	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ritonavir inhibits the activity of SLC10A1			[28]
Adenosine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Adenosine induces the activity of SLC10A1			[29]
Irbesartan	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Irbesartan inhibits the activity of SLC10A1			[30]
Drug in Phase 3 Trial
Oltipraz	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Oltipraz inhibits the expression of SLC10A1			[10]
Afimoxifene	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Afimoxifene inhibits the expression of SLC10A1			[24]
Sulforafan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sulforafan inhibits the expression of SLC10A1			[40]
Drug in Phase 2 Trial
LUM001	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	LUM001 inhibits the activity of SLC10A1			[43]
Drug in Phase 1 Trial
Sodium arsenite	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sodium arsenite inhibits the expression of SLC10A1			[37]
TAK-875	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	TAK-875 inhibits the activity of SLC10A1			[42]
Investigative Drug
Bromsulphthalein	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bromsulphthalein inhibits the transportation of Sodium taurocholate by SLC10A1 (IC50 = 7.3 microM)			[2]
Affected Drug/Substrate	Sodium taurocholate	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-NTCP
Beta-naphthoflavone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Beta-naphthoflavone inhibits the expression of SLC10A1			[32]
Baohuoside I	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Baohuoside I increases the expression of SLC10A1			[41]
Patented Pharmaceutical Agent
Ro-41-5253	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ro-41-5253 inhibits the expression of SLC10A1			[17]
Regulation Mechanism	via the inhibition of Retinoic acid receptor alpha (RARA)			Transcription Factor Info
Cell System	Human hepatocellular carcinoma (HepaRG)
Natural Product
Cigarette smoke condensate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cigarette smoke condensate inhibits the transportation of Taurocholate by by repressing mRNA expression of SLC10A1 (IC50 = 140 microM)			[5]
Affected Drug/Substrate	Taurocholate	Modulation Type	Inhibition
Cell System	Human hepatoma HepaRG cells-NTCP
Boldine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Boldine induces the activity of SLC10A1			[8]
Cell System	Model organism in vivo (rat)
Coal Ash	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Coal Ash inhibits the expression of SLC10A1			[31]
Particulate Matter	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Particulate Matter inhibits the expression of SLC10A1			[34]
Heliotrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Heliotrine inhibits the expression of SLC10A1			[35]
Tobacco Smoke Pollution	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tobacco Smoke Pollution inhibits the expression of SLC10A1			[5]
Methyleugenol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methyleugenol inhibits the expression of SLC10A1			[38]
Dietary Constituent
Apple juice	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Apple juices inhibits the transportation of Fexofenadine by SLC10A1			[4]
Affected Drug/Substrate	Fexofenadine	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-NTCP
DT Modulation2	Apple juice inhibits the transportation of Sodium taurocholate by SLC10A1			[4]
Affected Drug/Substrate	Sodium taurocholate	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-NTCP
Environmental toxicant
Tetrabromobisphenol A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tetrabromobisphenol A inhibits the activity of SLC10A1			[36]
Polychlorinated dibenzodioxin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Polychlorinated dibenzodioxin inhibits the expression of SLC10A1			[5]
Mycotoxins
Aflatoxin B1	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Aflatoxin B1 inhibits the expression of SLC10A1			[38]
DT Modulation2	Aflatoxin B1 affects the expression of SLC10A1 protein			[15]
Regulation Mechanism				Transcription Factor Info
Carcinogen
Benzo(a)pyrene	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Benzo(a)pyrene inhibits the expression of SLC10A1			[38]
Cyanotoxin
Cylindrospermopsin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cylindrospermopsin inhibits the expression of SLC10A1			[33]
cylindrospermopsin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	cylindrospermopsin results in decreased expression of SLC10A1 mRNA			[33]
Regulation Mechanism				Transcription Factor Info
Pesticide/Insecticide
Dieldrin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dieldrin inhibits the expression of SLC10A1			[16]
Endosulfan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Endosulfan inhibits the expression of SLC10A1			[16]
Heptachlor	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Heptachlor inhibits the expression of SLC10A1			[16]
DDT	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	DDT results in decreased expression of SLC10A1 mRNA			[16]
Regulation Mechanism				Transcription Factor Info
Health and Environmental Toxicant
Chlordan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chlordan inhibits the expression of SLC10A1			[16]
Perfluorooctane sulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Perfluorooctane sulfonic acid increases the expression of SLC10A1			[39]

References
1	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
2	Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther. 1999 Dec;291(3):1204-9.
3	Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther. 2007 Jun;321(3):1170-8.
4	Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002 Jan;71(1):11-20.
5	Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate. Toxicology. 2016 Jul 1;363-364:58-71.
6	Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82.
7	Effect of mTOR inhibitors on sodium taurocholate cotransporting polypeptide (NTCP) function in vitro. Front Pharmacol. 2023 Mar 22;14:1147495.
8	Boldine attenuates cholestasis associated with nonalcoholic fatty liver disease in hereditary hypertriglyceridemic rats fed by high-sucrose diet. Physiol Res. 2015;64 Suppl 4:S467-76.
9	Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. Am J Physiol Gastrointest Liver Physiol. 2005 Nov;289(5):G798-805.
10	Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos. 2006 Oct;34(10):1756-63.
11	Transcriptional profiling in the human prefrontal cortex: evidence for two activational states associated with cocaine abuse. Pharmacogenomics J. 2003;3(1):27-40.
12	The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol. 2005 Aug;68(2):551-8.
13	Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
14	Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
15	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
16	Regulation of hepatic drug transporter activity and expression by organochlorine pesticides. J Biochem Mol Toxicol. 2014 Mar;28(3):119-28.
17	Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression. J Biol Chem. 2015 Feb 27;290(9):5673-84.
18	Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
19	Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?. Toxicol Sci. 2016 Jan;149(1):237-50.
20	UDCA and CDCA alleviate 17alpha-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats. Toxicol Appl Pharmacol. 2016 Nov 15;311:12-25.
21	From the Cover: MechanisticInsights in Cytotoxic and Cholestatic Potential of the Endothelial Receptor Antagonists Using HepaRG Cells. Toxicol Sci. 2017 Jun 1;157(2):451-464.
22	Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
23	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
24	The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes. Arch Toxicol. 2018 Mar;92(3):1099-1112.
25	Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172.
26	Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology. 2000 Jul;32(1):82-6.
27	Multihormonal regulation of hepatic sinusoidal Ntcp gene expression. Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G782-94.
28	Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther. 2006 Sep;318(3):1068-75.
29	Short-term regulation of bile acid uptake by microfilament-dependent translocation of rat ntcp to the plasma membrane. Hepatology. 1999 Jul;30(1):223-9.
30	Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm. 2013 Mar 4;10(3):1008-19.
31	Endothelial effects of emission source particles: acute toxic response gene expression profiles. Toxicol In Vitro. 2009 Feb;23(1):67-77.
32	Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
33	Modulation of chromatin remodelling induced by the freshwater cyanotoxin cylindrospermopsin in human intestinal caco-2 cells. PLoS One. 2014 Jun 12;9(6):e99121.
34	Regulation of human hepatic drug transporter activity and expression by diesel exhaust particle extract. PLoS One. 2015 Mar 24;10(3):e0121232.
35	Disturbance of gene expression in primary human hepatocytes by hepatotoxic pyrrolizidine alkaloids: A whole genome transcriptome analysis. Toxicol In Vitro. 2015 Oct;29(7):1669-82.
36	Inhibition of SLC drug transporter activities by environmental bisphenols. Toxicol In Vitro. 2017 Apr;40:34-44.
37	Cellular and Molecular Effects of Prolonged Low-Level Sodium Arsenite Exposure on Human Hepatic HepaRG Cells. Toxicol Sci. 2018 Apr 1;162(2):676-687.
38	Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
39	High-Throughput Transcriptomic Analysis of Human Primary Hepatocyte Spheroids Exposed to Per- and Polyfluoroalkyl Substances as a Platform for Relative Potency Characterization. Toxicol Sci. 2021 May 27;181(2):199-214.
40	Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664.
41	Baohuoside I inhibits FXR signaling pathway to interfere with bile acid homeostasis via targeting ER alpha degradation. Cell Biol Toxicol. 2022 Jul 8.
42	Quantitative Systems Toxicology Analysis of In Vitro Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury. Toxicol Sci. 2019 Feb 1;167(2):458-467.
43	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
44	Uremic solutes modulate hepatic bile acid handling and induce mitochondrial toxicity. Toxicol In Vitro. 2019;56:52-61.
45	In silico identification of potential cholestasis-inducing agents via modeling of Na(+)-dependent taurocholate cotransporting polypeptide substrate specificity. Toxicol Sci. 2012;129(1):35-48.
46	Testing in vitro tools for the prediction of cholestatic liver injury induced by non-pharmaceutical chemicals. Food Chem Toxicol. 2021;152:112165.
47	Carvedilol impairs bile acid homeostasis in mice: implication for nonalcoholic steatohepatitis. Toxicol Sci. 2023;196(2):200-217.
48	Integration of transcriptomic, proteomic and metabolomic data to reveal the biological mechanisms of AAI injury in renal epithelial cells. Toxicol In Vitro. 2021;70:105054.
49	Reduction of CXC chemokine receptor 3 in an in vitro model of continuous exposure to asbestos in a human T-cell line, MT-2. Am J Respir Cell Mol Biol. 2011;45(3):470-9.
50	Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
51	Substrate Specificities and Inhibition Pattern of the Solute Carrier Family 10 Members NTCP, ASBT and SOAT. Front Mol Biosci. 2021;8:689757.
52	Identification of potential target genes of ROR-alpha in THP1 and HUVEC cell lines. Exp Cell Res. 2017;353(1):6-15.
53	Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46.
54	Comparative case study on NAMs: towards enhancing specific target organ toxicity analysis. Arch Toxicol. 2024;98(11):3641-3658.
55	Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC). Arch Toxicol. 2024;98(10):3409-3424.
56	Different dose-dependent mechanisms are involved in early cyclosporine a-induced cholestatic effects in hepaRG cells. Toxicol Sci. 2014;141(1):244-53.
57	Cellular Accumulation and Toxic Effects of Bile Acids in Cyclosporine A-Treated HepaRG Hepatocytes. Toxicol Sci. 2015;147(2):573-87.
58	Transport of the soy isoflavone daidzein and its conjugative metabolites by the carriers SOAT, NTCP, OAT4, and OATP2B1. Arch Toxicol. 2015;89(12):2253-63.
59	Development of stably transfected human and rat hepatoma cell lines for the species-specific assessment of xenobiotic response enhancer module (XREM)-dependent induction of drug metabolism. Toxicology. 2010;277(1-3):11-9.
60	The role of the farnesoid X receptor in quadruple anti-tuberculosis drug-induced liver injury. Toxicology. 2022;476:153256.
61	Apical Sodium-Dependent Bile Acid Cotransporter, A Novel Transporter of Indocyanine Green, and Its Application in Drug Screening. Int J Mol Sci. 2020;21(6).
62	Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis. Chem Res Toxicol. 2016 Oct 17;29(10):1778-1788.
63	Kinetic characterization of bile salt transport by human NTCP (SLC10A1). Toxicol In Vitro. 2018;46:189-193.
64	In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of hydroxybutyrate (GHB) binding. Toxicol In Vitro. 2017;40:196-202.
65	A multi-omics approach to elucidate okadaic acid-induced changes in human HepaRG hepatocarcinoma cells. Arch Toxicol. 2024;98(9):2919-2935.
66	Na+/Taurocholate Cotransporting Polypeptide and Apical Sodium-Dependent Bile Acid Transporter Are Involved in the Disposition of Perfluoroalkyl Sulfonates in Humans and Rats. Toxicol Sci. 2015;146(2):363-73.
67	Perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), and perfluorononanoic acid (PFNA) increase triglyceride levels and decrease cholesterogenic gene expression in human HepaRG liver cells. Arch Toxicol. 2020 Sep;94(9):3137-3155.
68	Impairment of bile acid metabolism by perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) in human HepaRG hepatoma cells. Arch Toxicol. 2020 May;94(5):1673-1686.
69	Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754.
70	New Approach Methods for Hazard Identification: A Case Study with Azole Fungicides Affecting Molecular Targets Associated with the Adverse Outcome Pathway for Cholestasis. Cells. 2022;11(20).
71	Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
72	Polarized location of SLC and ABC drug transporters in monolayer-cultured human hepatocytes. Toxicol In Vitro. 2015;29(5):938-46.
73	Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1. Drug Metab Dispos. 2014;42(11):1780-4.
74	Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury. Toxicol Sci. 2017;157(1):50-61.
75	In vitro inhibition of OATP-mediated uptake of phalloidin using bile acid derivatives. Toxicol Appl Pharmacol. 2009;239(1):13-20.
76	Cross-species comparisons of transcriptomic alterations in human and rat primary hepatocytes exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Sci. 2012 May;127(1):199-215.
77	High-Throughput Transcriptomics of Nontumorigenic Breast Cells Exposed to Environmentally Relevant Chemicals. Environ Health Perspect. 2024;132(4):47002.
78	Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021;22(20).

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Exogenous Modulation

Visitor Map

Correspondence